Pacira Biosciences, Inc. (PCRX)
36.34
+0.02
(+0.04%)
USD |
NASDAQ |
Oct 16, 16:00
36.34
0.00 (0.00%)
After-Hours: 20:00
Pacira Biosciences Research and Development Expense (Annual) : 117.31M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 117.31M |
| December 31, 2024 | 81.58M |
| December 31, 2023 | 76.26M |
| December 31, 2022 | 84.80M |
| December 31, 2021 | 55.54M |
| December 31, 2020 | 59.42M |
| December 31, 2019 | 72.12M |
| December 31, 2018 | 55.69M |
| December 31, 2017 | 57.29M |
| December 31, 2016 | 45.68M |
| Date | Value |
|---|---|
| December 31, 2015 | 28.66M |
| December 31, 2014 | 18.73M |
| December 31, 2013 | 21.56M |
| December 31, 2012 | 9.937M |
| December 31, 2011 | 14.87M |
| December 31, 2010 | 18.63M |
| December 31, 2009 | 26.23M |
| December 31, 2008 | 33.21M |
| December 31, 2007 | 20.61M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Viatris, Inc. | 952.50M |
| Johnson & Johnson | 14.83B |
| Liquidia Corp. | 38.45M |
| Organon & Co. | 366.00M |
| ANI Pharmaceuticals, Inc. | 51.66M |